1. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert C, Kopin IJ. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979; 1: 249–254.
2. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980.
3. Langston JW, Langston EB, Irwin I. MPTP-induced parkinsonism in human and non-human primates — clinical and experimental aspects. Acta Neurol Scand 1984; 100 (Suppl.): 49–54.
4. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984; 311: 467–469.
5. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Europ J Pharmacol 1984; 106: 209–210.